AOD9604
AOD9604 (Anti-Obesity Drug 9604) is a modified C-terminal fragment of human growth hormone (hGH 177-191 + tyrosine), orally active, lipolytic peptide that mimics without anabolic/GH sides (no IGF-1 surge). Developed by Metabolic Pharmaceuticals, Phase 2b trials showed 2–3kg loss over 12 weeks—focus on obesity, osteoarthritis.
Edge: Selective β3-adrenergic activation → fat-specific.
Mechanism
- Lipolysis: ↑HSL in adipocytes (no receptors on muscle).
- Fatty Acid Oxidation: Mitochondrial β-ox ↑.
- No Hyperglycemia: Unlike full GH.
- Cartilage: Stimulates chondrocytes (OA trials).
PK: Oral/sublingual best; half-life ~4h.
Research Evidence
| Study/Model | Outcomes |
|---|---|
| Phase 2b Obesity (544 patients) | -2.8kg vs. placebo (12w, 1mg oral daily). |
| Animal Fat Loss | 50% visceral reduction (obese mice). |
| OA Knee | Pain ↓28%, function ↑ (Phase 2, Osteoarthritis Cartilage 2013). |
| Safety | No IGF-1, glucose, or cancer signals. |
Protocols (Research)
| Goal | Dose (mg/day) | Route/Frequency | Cycle |
|---|---|---|---|
| Fat Loss | 0.3–1mg | Oral fasted AM | 12–24 weeks |
| Local Fat | 1–2mg | Sublingual | Ongoing |
| Joint/OA | 0.5–1mg | Oral daily | 8–12 weeks |
| Stack | 1mg + CJC/Ipa | GH synergy | 12 weeks |
- Oral: Tablets/caps; empty stomach.
Benefits
- Targeted Lipolysis: Visceral/abdominal focus.
- No Muscle/Anabolism: Pure fat loss.
- Joint Health: Cartilage matrix support.
- Metabolic: Lipids ↑HDL, no insulin resistance.
- Clean: No HPTA/IGF impact.
Side Effects & Safety
| Minimal Reported | Rare | Notes |
|---|---|---|
| Mild headache | None significant | Cleanest fat-loss peptide |
| GI (high oral) | None | Phase 3 safe |
Comparisons
| Peptide/Drug | Fat Loss Mechanism | Muscle Effect | Oral? |
|---|---|---|---|
| AOD9604 | Lipolytic Frag | None | Yes |
| HGH Frag 176-191 | Similar | None | Poor |
| Semaglutide | GLP-1 Appetite | Mod loss | No |
| Clenbuterol | β2 Agonist | Catabolic | Yes |
Status
- Research Chemical: Australian Phase 3 OA failed (funding); obesity orphan potential.
- UK: Oral research formulations.
- Patents: Expired generics.
Disclaimer: Research-only; body comp tracking advised.
Reviews
There are no reviews yet.
Related products
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Metabolic and Appetite Pathway Research
Be the first to review “AOD9604”